Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

US-based pharmaceutical company Eli Lilly on Thursday announced that its experimental oral GLP-1 pill, named orforglipron, ...

The Gila monster is a large, magnificent, and venomous desert-dwelling reptile found throughout the southwestern US and Mexico. A toxic bite from the Gila can cause searing pain, loss of consciousness ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Victoza, produced by Novo Nordisk, holds FDA approval for regulating blood sugar levels among individuals diagnosed with type ...

New research has highlighted the contribution of metabolic pathways and the gut–joint axis in osteoarthritis, pinpointing new ...

The University will not surrender its independence or relinquish its constitutional rights. Neither Harvard nor any other ...

BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved.

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive ...